Clinical Advances in Hematology & Oncology最新文献_第3页

Highlights in chronic lymphocytic leukemia from the 67th ASH Annual Meeting and Exposition: commentary. 第67届ASH年会暨博览会慢性淋巴细胞白血病的亮点：评论。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-01-01

Susan O'Brien

引用次数: 0

Multikinase inhibitors in refractory metastatic colorectal cancer: an optimal sequence? 多激酶抑制剂治疗难治性转移性结直肠癌：最佳序列？

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-01-01

Celine Hoyek, Angelo Pirozzi, Naohiro Okano, Jennah J Bauernfeind, Jeremy Jones, Tanios Bekaii-Saab

{"title":"Multikinase inhibitors in refractory metastatic colorectal cancer: an optimal sequence?","authors":"Celine Hoyek, Angelo Pirozzi, Naohiro Okano, Jennah J Bauernfeind, Jeremy Jones, Tanios Bekaii-Saab","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Despite major advances in management strategies, metastatic colorectal cancer remains an important clinical challenge because most patients experience progression after standard first- and secondline treatments. In the setting of refractory disease, defined as disease that progresses after 2 or more lines of treatment, the therapeutic landscape is growing. Options include regorafenib, trifluridine plus tipiracil (FTD/TPI) with or without bevacizumab, and fruquintinib, all of which received approval from the US Food and Drug Administration after showing modest survival benefits in phase 3 trials. However, optimal sequencing remains undefined owing to the absence of direct comparative studies. Real-world data suggest that sequencing regorafenib before FTD/TPI may improve outcomes, with the addition of bevacizumab to FTD/TPI offering further survival benefit. Fruquintinib has also shown efficacy after the use of regorafenib and/or FTD/TPI. Therefore, treatment decisions are based on a case-by-case scenario, with factors such as comorbidities, preferred route of administration, and tolerability taken into consideration. Additionally, improved patient stratification with biomarker testing has become essential for guiding personalized treatment selection. This review highlights the current evidence and gaps in sequencing strategies for the treatment of refractory metastatic colorectal cancer, highlighting the need for future research to inform personalized, effective, and sustainable treatment pathways.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 1","pages":"22-28"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146259964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of ravulizumab in a pregnant patient with PNH: case-based insights. 在妊娠PNH患者中使用ravulizumab：基于病例的见解。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-01-01

Bhumika J Patel

引用次数: 0

Access to novel cancer drugs in low- and middle-income countries. 在低收入和中等收入国家获得新型抗癌药物。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-12-01

Amol Patel

引用次数: 0

Ravulizumab-danicopan combination therapy in PNH management. Ravulizumab-danicopan联合治疗PNH。